The first COVID-19 vaccines have now been administered in Qatar and around the world, offering hope that an end to the pandemic could be in sight. Professor of Teaching in Microbiology and Immunology at Weill Cornell Medicine in Qatar (WMC-Q), DrAli Sultan, says if the ongoing vaccination campaign goes well, herd immunity could be reached by end of summer and situation closer to normal by the end of 2021.
How would you see the pre-COVID vaccine and post COVID vaccine times?Scientists, including myself, are very excited at the prospect of an effective vaccine and the prospect of returning to normality. Starting a mass vaccination program is an important first step towards ending this pandemic. And it has come relatively quickly. Producing an effective vaccine against an infectious disease is a long process that in the past has usually taken many years. The development of the COVID-19 vaccine within a span of 8-9 months, on the other hand, has been extraordinarily fast. It has shown how quickly scientific development can be achieved via collaborative hard work, and how much the will can produce the means.
In addressing the above question, I will consider the following issues:1: What next after vaccination: One has to remember that COVID-19 vaccine won't be available immediately for everybody. Early evidence suggests that the available vaccines reduce peoples risk of developing COVID-19 by around 80-95 percent. Coronavirus is likely to continue its rapid spread until a large majority of the population is vaccinated or has survived a natural infection. The bottom line is that although an effective vaccine will certainly diminish greatly the relative risk of transmission, we still should not completely abandon basic public health measures, including the wearing of masks, hand hygiene and physical distancing.
2: Another issue to consider is re-infection, though rare, may still occur. Hence, strict practice of physical distancing, wearing a mask when in public, and frequent hand washing remain key. In the winter, it is particularly important to not gather indoors in small or large groups. Also, get a flu shot.
3: Post-COVID effect on the health of those infected: We are just beginning to learn more about the after effects of the infection. Some people, now referred to as long-haulers, are also reporting that their COVID symptoms keep dragging on for weeks. These symptoms include everything from headaches and cognitive problems to mood changes, fatigue, decreased exercise tolerance, and body ache.
4: The most important lessons that that this pandemic taught us are:a) Science and data should guide our decision now and in the future.b) Practicing good hygienic measures in hospitals, schools and other public places, could drastically reduce the spread and thereby eliminate new cases of COVID-19 and help to protect us from other infectionsc) Health authorities and government bodies should have plans and preparedness programs in place in order to avoid future pandemics.d) The COVID-19 pandemic has been a test, demonstrating that multilateral cooperation is the key to overcoming global challenges.
The first COVID-19 vaccines have now been administered in Qatar and around the world, offering hope that an end to the pandemic could be in sight: How long could it take to reach this in reality?If the ongoing vaccination campaign goes well, herd immunity could be reached by end of summer and situation closer to normal by the end of 2021. This estimate is dependent on significant numbers of people in Qatar and around the world being willing to be vaccinated with one of several vaccines in various stages of development.
If 75% to 80% of people are vaccinated, then we should reach the herd immunity threshold by the end of summer and by the time we may actually have enough herd immunity protecting our society that as we get to the end of 2021. This may allow us to reach some degree of normality that is close to where we were before the pandemic. If vaccination levels are significantly lower, (for example less than 50%), it could take a very long time to reach that level of protection and herd immunity.
Confidence in the COVID-19 vaccine grows, but at same time global concerns about side effects are on the rise: How could the confidence be built in people?There are number of surveys done on vaccine confidence, which showed that strong intent to get a COVID-19 vaccine has risen in countries like USA, UK, China, Brazil, Australia and South Korea. One of the main reasons for people who dont want to get a COVID-19 vaccine is concern about side effects. Even in countries where vaccines available to wider sections of the population, one hurdle will be public resistance to vaccination, or what is known as vaccine hesitancy or anti-vaxxers. Through the following facts and information we can build the people confidence in taking the COVID-19 vaccine:1. The first fact is that the public health authority in each country and the media have important role to play by explaining that there are some temporary side effects that happen with any vaccine injection such as pain at the site of the injection, mild fever, aches and sometimes headaches. These temporary side effects are good news because it means that the vaccine is doing its job by stimulating the immune system to fight. So it is common for highly effective vaccines to give people some symptoms. This is a sign the vaccine is doing what it was meant to do: Wake up the immune system and prepare it to fight off an infection in the future.2. The second fact is that COVID-19 vaccines do not contain a live or whole coronavirus, so the vaccinated person cant get COVID-19 from the vaccine.3. COVID-19 vaccines do not contain microchips or tracer technology.
There has been a lot of debate on whether people who had COVID-19 shall/shall not take the vaccine, whats your intake on that?The current data pointing to the fact that the people who have become sick with COVID-19 have some immunity, but we don't have enough evidence about antibody persistence to confidently say recovered patients are protected. Data suggest that immunity to SARS-CoV-2 from infection lasts at least 6-8 months, but we don't know enough yet about the degree to which previous infection confers immunity.We know that cases of reinfection have been documented; they appear to be rare. Likewise, an asymptomatic reinfection may go unnoticed, yet the individual may still transmit it to others. It would not be good if that person happens to be a healthcare worker. So, there is an argument to vaccine healthcare workers, even if they got infected because vaccines provide more robust immune protection than natural infection. Those at the highest risk of spreading the virus and those who might be tipping ICU capacity over the limit, are the ones who should be first in line for immunization.
Regarding the new COVID-19 variants that appeared in some countries, will the vaccine be effective in stopping them?New mutations of the coronavirus have been reported, which may change the nature of the proteins on its surface. This has led to fears that the vaccines developed so far may or may not work against these new variants because vaccines are based on teaching the body to recognize those proteins and attack them in future.The new mutations in the SARS-CoV-2 virus detected in UK created a new variant that is more transmissible than the earlier variants. However, there is no evidence that the new mutations seen in the SARS-CoV-2 will affect the vaccine efficacy or increase the severity of COVID-19.The vaccines teach the body about multiple spike proteins on the virus surface, and those spikes are also what the virus uses to get inside our cells. So a change in one protein because of a mutation doesnt automatically make the whole vaccine useless. But its important to keep looking for mutations in the coronavirus thats infecting people now. This will help researchers working on the vaccine field to know if we need to change the current vaccines or make new vaccines against COVID-19.Meanwhile, scientists are still studying whether changes in the coronavirus are making it more likely to infect children and teenagers. It will take time to find all these things out. Thats why its important to continue to wear masks in public, and stay away from large gatherings and unmasked interactions with people who dont live with you.
Read also
The rest is here:
Herd immunity could be reached by end of summer: Weill Cornell Medicine-Qatar immunology expert - The Peninsula Qatar
- Immunology Startup Ouro Sets Out With $120M for Drugs That Reset the Immune System - MedCity News - January 15th, 2025 [January 15th, 2025]
- Scipher Medicine and Atropos Health Partner to Accelerate Precision Medicine and Expand the Immunology Multimodal Network - Business Wire - December 23rd, 2024 [December 23rd, 2024]
- AbbVie to expand immunology pipeline with $200m Nimble Therapeutics acquisition - PMLiVE - December 23rd, 2024 [December 23rd, 2024]
- Sir Gustav Nossal Professor of Immunology to honour giant of Australian science - Walter and Eliza Hall Institute of Medical Research - December 9th, 2024 [December 9th, 2024]
- Research Assistant in Immunology - Surrey, United Kingdom job with UNIVERSITY OF SURREY | 384335 - Times Higher Education - November 28th, 2024 [November 28th, 2024]
- Reflecting on Pioneering organoids and 3D cell cultures for animal and human health - British Society for Immunology | - November 28th, 2024 [November 28th, 2024]
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET - Business Wire - November 20th, 2024 [November 20th, 2024]
- TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development - Business Wire - November 20th, 2024 [November 20th, 2024]
- Discovering Solutions for Long COVID: A T-Cell Immunology Breakthrough - Infection Control Today - November 20th, 2024 [November 20th, 2024]
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET IPH6501 - The Bakersfield Californian - November 20th, 2024 [November 20th, 2024]
- Immunology Data Shows INOVIO's INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of... - November 20th, 2024 [November 20th, 2024]
- What it's like in allergy and immunology: Shadowing Dr. Fraser - American Medical Association - November 12th, 2024 [November 12th, 2024]
- Dr. Naba Sharif Elected President of the New Jersey Allergy Asthma and Immunology Society - Newswire - November 12th, 2024 [November 12th, 2024]
- Department of Microbiology and Immunology Named a National Milestones Program - Stony Brook News - October 26th, 2024 [October 26th, 2024]
- Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting - businesswire.com - October 26th, 2024 [October 26th, 2024]
- Remembering immunology educator, researcher Tom McDonald, PhD - University of Nebraska Medical Center - October 13th, 2024 [October 13th, 2024]
- Systems immunology approaches to study T cells in health and disease - Nature.com - October 13th, 2024 [October 13th, 2024]
- Leading the charge to discover answers in immunology - The University of Arizona - October 2nd, 2024 [October 2nd, 2024]
- New mouse models offer valuable window into COVID-19 infection - La Jolla Institute for Immunology - October 2nd, 2024 [October 2nd, 2024]
- Wide-Moat AbbVie Poised for Growth, Driven by Innovation in Immunology Beyond Humira - Morningstar - October 2nd, 2024 [October 2nd, 2024]
- Lilly's immunology unit scores another FDA nod with eczema treatment Ebglyss - FiercePharma - September 23rd, 2024 [September 23rd, 2024]
- Huang Named Head Of Pathology And Immunology - Mirage News - September 15th, 2024 [September 15th, 2024]
- Huang named head of pathology & immunology - Washington University School of Medicine in St. Louis - September 15th, 2024 [September 15th, 2024]
- Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit - Yahoo Finance - September 15th, 2024 [September 15th, 2024]
- Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit - StockTitan - September 15th, 2024 [September 15th, 2024]
- UCLA receives $120 million from Alya and Gary Michelson for new California Institute for Immunology and Immunotherapy - UCLA Newsroom - September 2nd, 2024 [September 2nd, 2024]
- Boosting vaccines for the elderly with 'hyperactivators' - Boston Children's Answers - Boston Children's Discoveries - June 27th, 2024 [June 27th, 2024]
- Immunologists Want You to Know These Dust Mite Allergy Facts - Yahoo Lifestyle UK - June 27th, 2024 [June 27th, 2024]
- How Ragon Institute's new building aids its mission Harvard Gazette - Harvard Gazette - June 27th, 2024 [June 27th, 2024]
- Insights into CRS and NPs: Visual and Bibliometric Analysis - Physician's Weekly - June 27th, 2024 [June 27th, 2024]
- Biogen joins immunology wave with $1.15 billion acquisition of HI-Bio - STAT - May 24th, 2024 [May 24th, 2024]
- Biogen Buys Desired Growth In Immunology With $1.15bn Hi-Bio Deal - Scrip - May 24th, 2024 [May 24th, 2024]
- Biogen Boosts Immunology Portfolio with $1.8 Billion Acquisition of HI-Bio - BioPharm International - May 24th, 2024 [May 24th, 2024]
- Owkin Unveils AI-Driven Oncology and Immunology Pipeline, In-Licenses Best-in-Class Asset OKN4395 - Yahoo Finance - May 24th, 2024 [May 24th, 2024]
- Biogen to expand immunology and rare disease portfolio with $1.8bn HI-Bio acquisition - PMLiVE - May 24th, 2024 [May 24th, 2024]
- Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress - Business Wire - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in deal worth up to $1.8B - MM+M Online - May 24th, 2024 [May 24th, 2024]
- COVID-19 Re-Vaccinations Elicit Neutralizing Antibodies Against Future Variants - Technology Networks - May 24th, 2024 [May 24th, 2024]
- HIV Vaccine Candidate Induces Broadly Neutralizing Antibodies in Humans - Technology Networks - May 24th, 2024 [May 24th, 2024]
- Pasteur Fiocruz Center on Immunology and Immunotherapy is inaugurated in Cear - Fiocruz - May 24th, 2024 [May 24th, 2024]
- Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal - Marketscreener.com - May 24th, 2024 [May 24th, 2024]
- Fellow Focus in Four: Marat Kribis, MD, Rheumatology, Allergy and Immunology - Yale School of Medicine - April 15th, 2024 [April 15th, 2024]
- Long COVID Can Now Be Detected in the Blood - Technology Networks - April 15th, 2024 [April 15th, 2024]
- Rimjhim Agarwal selected as Major Symposium speaker at the American Association of Immunologists ... - La Jolla Institute for Immunology - March 29th, 2024 [March 29th, 2024]
- Seeking new horizons: Where innovators find opportunities in a fast-changing immunology landscape - IQVIA - March 29th, 2024 [March 29th, 2024]
- Researchers identify new way to inhibit immune cells that drive allergic asthma - EurekAlert - March 29th, 2024 [March 29th, 2024]
- Innovation in Oncology and Cancer Immunology Research - Boehringer Ingelheim - March 29th, 2024 [March 29th, 2024]
- Measles outbreaks show the risk of under-vaccination | News | Harvard T.H. Chan School of Public Health - HSPH News - March 29th, 2024 [March 29th, 2024]
- Immunology-oncology ELISA Kits Market to Witness a Healthy Growth by 2030 - WhaTech - March 29th, 2024 [March 29th, 2024]
- Spring Allergy Season Is Getting Worse. Here's What to Know. - The New York Times - March 29th, 2024 [March 29th, 2024]
- Multiple sclerosis has distinct subtypes, study finds, pointing to different treatments - STAT - March 29th, 2024 [March 29th, 2024]
- Researchers identify viable vaccine targets for hepatitis C infections - News-Medical.Net - March 29th, 2024 [March 29th, 2024]
- Three research projects awarded funding from the Immunology Institute Pilot Project program - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE - Scrip - February 29th, 2024 [February 29th, 2024]
- AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology ... - PR Newswire - February 29th, 2024 [February 29th, 2024]
- Integrating single-cell multi-omics and prior biological knowledge for a functional characterization of the immune system - Nature.com - February 29th, 2024 [February 29th, 2024]
- Renowned immunologist and four-decade UAB researcher Max Cooper, M.D., will deliver this year's Marx Lecture - University of Alabama at Birmingham - February 29th, 2024 [February 29th, 2024]
- Inactivation of TGF- signaling in CAR-T cells | Cellular & Molecular Immunology - Nature.com - February 29th, 2024 [February 29th, 2024]
- Babies use their immune system differently but efficiently | Cornell Chronicle - Cornell Chronicle - February 29th, 2024 [February 29th, 2024]
- Antibody reduces allergic reactions to multiple foods in NIH clinical trial - National Institutes of Health (NIH) (.gov) - February 29th, 2024 [February 29th, 2024]
- Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Development of its ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Theratechnologies announces publication in Frontiers in Immunology on TH1902 - TipRanks.com - TipRanks - February 21st, 2024 [February 21st, 2024]
- Smoking has long-term effects on the immune system - Institut Pasteur - February 21st, 2024 [February 21st, 2024]
- Spring Allergies Attack More Than Just Your Nose - ACAAI Public Website - American College of Allergy Asthma and Immunology - February 21st, 2024 [February 21st, 2024]
- Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel ... - GlobeNewswire - February 21st, 2024 [February 21st, 2024]
- Shikhar Mehrotra named co-leader of Cancer Biology and Immunology research program at MUSC Hollings - The Cancer Letter - January 27th, 2024 [January 27th, 2024]
- Gut Microbiome Benefits of Breast Milk Revealed in Mouse Study - Technology Networks - January 27th, 2024 [January 27th, 2024]
- Research on Immunological Diseases Launches with Hungarian Participation - Hungary Today - January 27th, 2024 [January 27th, 2024]
- UCLA to turn former shopping mall into centers for research on immunology and quantum science - The Associated Press - January 8th, 2024 [January 8th, 2024]
- TRexBio Announces a First Option Was Exercised by Partner under Immunology Discovery Collaboration - Business Wire - January 8th, 2024 [January 8th, 2024]
- UCLA to turn former Westside Pavilion into centers for research on immunology and quantum science - KABC-TV - January 8th, 2024 [January 8th, 2024]
- HI-Bio Announces $95 Million Series B Financing to Advance Targeted Therapies for Immune-Mediated Diseases - PR Newswire - January 8th, 2024 [January 8th, 2024]
- Beyond Cytotoxicity: The Importance of T Cell Memory - The Scientist - January 8th, 2024 [January 8th, 2024]
- IKAROS: Unlocking the secrets of the immune system's key player - News-Medical.Net - January 8th, 2024 [January 8th, 2024]
- UCLA to turn former shopping mall into centers for research on immunology and quantum science - The Caledonian-Record - January 8th, 2024 [January 8th, 2024]
- Revolutionizing Vaccine Research: The Power of a New Algorithm - SciTechDaily - December 31st, 2023 [December 31st, 2023]
- Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people ... - Nature.com - December 22nd, 2023 [December 22nd, 2023]
- Two new practice parameters offer recommendations for treating anaphylaxis and atopic dermatitis - News-Medical.Net - December 22nd, 2023 [December 22nd, 2023]
- Physician and Patient (Un)Wellness in Allergy and Immunology During COVID-19 and Beyond: Lessons for the Future - Physician's Weekly - December 22nd, 2023 [December 22nd, 2023]
- Researchers Identify Why Some Cancers Do Not Respond to Immunotherapy - NYU Langone Health - December 22nd, 2023 [December 22nd, 2023]